| Business Summary | | COR
Therapeutics,
Inc.
is
engaged
in
the
discovery,
development
and
marketing
of
novel
therapeutic
products
to
establish
new
standards
of
care
for
treating
and
preventing
acute
and
chronic
cardiovascular
diseases.
The
Company
is
marketing
Integrilin,
its
FDA-approved
drug,
to
treat
patients
with
acute
cardiovascular
disease.
The
Company
is
also
developing
a
portfolio
of
drugs
to
treat
and
prevent
a
broad
range
of
acute
and
chronic
cardiovascular
diseases
and
other
conditions.
In
addition
to
its
commercial
activities,
the
Company
continues
to
pursue
a
wide
array
of
research
and
development
programs
that
may
have
therapeutic
potential
for
a
variety
of
indications,
including
acute
coronary
syndromes,
stroke,
restenosis,
cancer,
and
venous
and
arterial
thrombosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | COR
Therapeutics,
Inc.
is
engaged
in
the
discovery,
development
and
commercialization
of
novel
pharmaceutical
products
to
establish
new
standards
of
care
for
the
treatment
and
prevention
of
severe
cardiovascular
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
42%
to
$60.8
million.
Net
income
totaled
$452
thousand
vs.
a
loss
of
$16.4
million.
Results
reflect
continued
strong
demand
for
INTEGRILIN,
improved
operating
margins
and
increased
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Vaughn Kailian, 56 Pres,
CEO | $784K | $4.9M | Charles Homcy, M.D., 52 Exec.
VP of R&D | 521K | 8.5M | Peter Roddy, 41 Sr.
VP-Fin., CFO | -- | -- | Patrick Broderick, 42 Sr.
VP, Gen. Counsel and Corp. Sec. | 365K | 3.3M | Lee Rauch, 47 Sr.
VP, Corp. Devel. | 378K | 1.2M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|